APA (7th ed.) Citation

AK, G., R, L., R, H., SP, P., L, P., C, J., . . . NL, B. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(11), 2524. https://doi.org/10.1158/1078-0432.CCR-19-2973

Chicago Style (17th ed.) Citation

AK, Gopal, et al. "First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26, no. 11 (2020): 2524. https://doi.org/10.1158/1078-0432.CCR-19-2973.

MLA (9th ed.) Citation

AK, Gopal, et al. "First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 11, 2020, p. 2524, https://doi.org/10.1158/1078-0432.CCR-19-2973.